Talk to our Consultant - Bladder Cancer Treatment Market Size

Global Bladder Cancer Treatment Market Research Report: Forecast (2022-2027)

By Diagnosis (Cystoscopy, Urine Tests, Imaging, Biopsy), By Cancer Type (Urothelial Carcinoma, Squamous Cell, Carcinoma, Adenocarcinoma), By Treatment (Surgery, Chemotherapy (Cisplatin, Gemcitabine, F... ... atin, Gemcitabine, Fluorouracil (5-FU), Mitomycin, Others (Doxorubicin, etc.)), Immunotherapy (Atezolizumab (Tecentriq), Avelumab (Bavencio), Nivolumab (Opdivo), Pembrolizumab (Keytruda), Enfortumab Vedotin (Padcev), Sacituzumab Govitecan (Trodelvy)), Radiation Therapy, Targeted Therapy (Erdafitinib (Balversa))), By End-User (Hospitals, Specialty Cancer Centers, Others (Ambulatory Surgery Centers, etc.)), By Region (North America, South America, Europe, Middle East & Africa, Asia-Pacific), By Country (The US, Canada, Mexico, Brazil, The UK, Germany, France, Italy, Spain, South Africa, GCC, China, Japan, India, Australia, South East Asia), By Company(AstraZeneca PLC, Bristol Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Novartis International AG, Pfizer Inc., Sanofi, Others) Read more

Healthcare
Jun 2022
Pages 189
Report Format: PDF, Excel, PPT

Market Definition

Bladder cancer is when the DNA in the bladder cells mutates and disables the cell growth functions. In many cases, these mutated cells either die or get attacked by the immune system. However, sometimes they might evade the immune system, multiply aggressively, and form a tumor in the bladder. So far, smoking is the most important risk factor for bladder cancer as tobacco has carcinogenic chemicals that pass into the bloodstream, and kidneys filter them into the urine.

Market Insights

The Global Bladder Cancer Market is projected to grow at a CAGR of around 4.6% during the forecast period, i.e., 2022-27. The growth of the market is driven primarily by the rapidly increasing instances of bladder cancer worldwide, coupled with the escalating focus of governments of different countries on developing robust medical infrastructure & increasing the overall healthcare expenditure.

Report Coverage	Details
Study Period	Historical Data: 2017-20
	Base Year: 2021
	Forecast Period: 2022-27
CAGR (2022-27)	4.6%
Regions Covered	North America: The US, Canada, Mexico
	Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe
	Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific
	South America: Brazil, Rest of Latin America
	Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa
Key Companies Profiled	AstraZeneca PLC, Bristol Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Novartis International AG, Pfizer Inc., Sanofi, Others
Unit Denominations	USD Million/Billion

Besides, massive R&D investments by the leading biotech & pharma companies in bringing advancements in the current diagnoses & treatments of bladder cancer and offering better success rates & effectiveness on patients are also driving the global market.

Governments across different countries are actively spreading awareness campaigns, advertisements, etc., among people about bladder cancer & the availability of effective therapies to cure the illness. In addition, with the rising geriatric population and higher possibilities of bladder cancer in those above 50 years, there are improved screening rates worldwide as a precautionary step, which projects lucrative prospects for the Global Bladder Cancer Market through 2027.

Impact of Covid-19 on the Global Bladder Cancer Market

In 2020, the Covid-19 pandemic introduced a paradigm shift in the functioning of different industries throughout the world & put immense pressure on the entire healthcare sector. The Bladder Cancer Market witnessed numerous unprecedented challenges associated with its global expansion, principally due to shifting priorities of the healthcare sector to address only Covid-19 patients.

As the effect of the Covid-19 virus was severe, governments of different countries imposed lockdowns & stringent movement restrictions to curb the spread of this dreadful disease. Consequently, such limitations restricted movements of all types and restrained non-critical patients from frequent hospital visits.

However, critical cases were addressed by doctors at hospitals while abiding by the safety norms. With digital transformations, healthcare professionals assisted their non-critical patients remotely using online platforms by exchanging reports & prescribing medications, parceling medications, & scheduling tests.

The most prominent challenges for the bladder cancer market during the pandemic were the halt in research operations and the unavailability of funds. Since governments of different countries invested massively in R&D for developing Covid-19 vaccines & cures, drug discoveries & developments associated with bladder cancer got temporarily suspended. Consequently, the leading players in the Global Bladder Cancer Market witnessed a downfall in revenue generation amidst the crisis.

Introduction
1. Research Process
2. Assumption
3. Market Segmentation
4. Market Definition
Executive Summary
Global Bladder Cancer Market Trends & Insights
Global Bladder Cancer Market Regulation & Policy, By Country
Global Bladder Cancer Market Dynamics
1. Growth Drivers
2. Challenges
3. Impact Analysis
Global Bladder Cancer Market Hotspot and Opportunities
Global Bladder Cancer Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
    1. Cystoscopy
    2. Urine Tests
    3. Imaging
    4. Biopsy
  2. By Cancer Type
    1. Urothelial Carcinoma
    2. Squamous Cell Carcinoma
    3. Adenocarcinoma
  3. By Treatment
    1. Surgery
    2. Chemotherapy
      1. Cisplatin
      2. Gemcitabine
      3. Fluorouracil (5-FU)
      4. Mitomycin
      5. Others (doxorubicin, etc.)
    3. Immunotherapy
      1. Atezolizumab (Tecentriq)
      2. Avelumab (Bavencio)
      3. Nivolumab (Opdivo)
      4. Pembrolizumab (Keytruda)
      5. Enfortumab vedotin (Padcev)
      6. Sacituzumab govitecan (Trodelvy)
    4. Radiation Therapy
    5. Targeted Therapy
      1. Erdafitinib (Balversa)
  4. By End-User
    1. Hospitals
    2. Specialty Cancer Centers
    3. Others (Ambulatory Surgery Centers, etc.)
  5. By Region
    1. North America
    2. South America
    3. Europe
    4. Middle East & Africa
    5. Asia-Pacific
  6. By Company
    1. Competition Characteristics
    2. Revenue Shares
    3. Competitor Placement in MarkNtel Advisor’s Quadrant
North America Bladder Cancer Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
  2. By Cancer Type
  3. By Treatment
  4. By End-User
  5. By Country
    1. The US
    2. Canada
    3. Mexico
South America Bladder Cancer Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
  2. By Cancer Type
  3. By Treatment
  4. By End-User
  5. By Country
    1. Brazil
    2. Rest of Latin America
Europe Bladder Cancer Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
  2. By Cancer Type
  3. By Treatment
  4. By End-User
  5. By Country
    1. The UK
    2. Germany
    3. France
    4. Italy
    5. Spain
    6. Rest of Europe
Middle East & Africa Bladder Cancer Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
  2. By Cancer Type
  3. By Treatment
  4. By End-User
  5. By Country
    1. South Africa
    2. GCC
    3. Rest of Middle East & Africa
Asia-Pacific Bladder Cancer Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
  2. By Cancer Type
  3. By Treatment
  4. By End-User
  5. By Country
    1. China
    2. Japan
    3. India
    4. Australia
    5. South East Asia
    6. Rest of Asia-Pacific
Global Bladder Cancer Market Key Strategic Imperatives for Success and Growth
Competitive Outlook
1. Competition Matrix
  1. By Application Portfolio
  2. Brand Specialization
  3. Target Markets
  4. Target by Applications
  5. Research & Development
  6. Strategic Alliances
  7. Strategic Initiatives
2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
  1. AstraZeneca PLC
  2. Bristol Myers Squibb
  3. Eli Lilly and Company
  4. F. Hoffmann-La Roche AG
  5. GlaxoSmithKline PLC
  6. Novartis International AG
  7. Pfizer Inc.
  8. Sanofi
  9. Others
Disclaimer

MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

Full Name*:

Company Name*:

Business Email*:

Country Name*:

Contact Number*:

Message:

Flexible Licensing Options

We offer flexible licensing options to cater to varying organizational needs. Choose the pricing pack that best suits your requirements:

Buy Now

Inquire Before Buying